Oculis Holding AG (NASDAQ:OCS) Sees Large Decline in Short Interest

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 25,600 shares, a decrease of 21.0% from the March 31st total of 32,400 shares. Based on an average trading volume of 51,100 shares, the short-interest ratio is presently 0.5 days. Approximately 0.1% of the company's shares are sold short.

Hedge Funds Weigh In On Oculis

Large investors have recently made changes to their positions in the business. abrdn plc bought a new stake in shares of Oculis during the fourth quarter valued at approximately $15,980,000. Compagnie Lombard Odier SCmA increased its position in shares of Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company's stock valued at $1,053,000 after acquiring an additional 30,750 shares in the last quarter. Searle & CO. bought a new stake in shares of Oculis during the fourth quarter valued at approximately $112,000. Wolverine Asset Management LLC bought a new stake in shares of Oculis during the third quarter valued at approximately $77,000. Finally, Barclays PLC bought a new stake in shares of Oculis during the second quarter valued at approximately $44,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Stock Performance

Shares of OCS stock traded up $0.07 during trading hours on Friday, hitting $12.02. 88,399 shares of the company's stock traded hands, compared to its average volume of 71,733. The stock's fifty day simple moving average is $11.85 and its two-hundred day simple moving average is $11.24. Oculis has a 12-month low of $9.05 and a 12-month high of $14.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.29 and a quick ratio of 5.29.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.04. The business had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.28 million. As a group, sell-side analysts predict that Oculis will post -1.72 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on OCS. HC Wainwright lowered their price objective on shares of Oculis from $29.00 to $28.00 and set a "buy" rating for the company in a research note on Wednesday. Chardan Capital restated a "buy" rating and issued a $30.00 price objective on shares of Oculis in a report on Tuesday, March 19th. Robert W. Baird lowered their price objective on shares of Oculis from $64.00 to $35.00 and set an "outperform" rating for the company in a report on Tuesday, March 19th. Finally, Wedbush restated an "outperform" rating and issued a $29.00 price objective on shares of Oculis in a report on Wednesday, March 6th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $29.14.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.